WHWK - Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.